Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. Lordick F, et al. Among authors: volovat c. Lancet Oncol. 2013 May;14(6):490-9. doi: 10.1016/S1470-2045(13)70102-5. Epub 2013 Apr 15. Lancet Oncol. 2013. PMID: 23594786 Clinical Trial.
Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
Novello S, Scagliotti GV, Sydorenko O, Vynnychenko I, Volovat C, Schneider CP, Blackhall F, McCoy S, Hei YJ, Spigel DR. Novello S, et al. Among authors: volovat c. J Thorac Oncol. 2014 Aug;9(8):1154-61. doi: 10.1097/JTO.0000000000000227. J Thorac Oncol. 2014. PMID: 25157768 Free article. Clinical Trial.
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
Maison-Blanche P, Vermorken JB, Goksel T, Machiels JP, Agarwala S, Rottey S, Daugaard G, Volovat C, Scheulen M, Sengeløv L, Grecea D, Eniu A, Jäger E, Meiri E, Cascinu S, Strumberg D, Demir G, Clemens M, Pinotti G, Nardi M, Guthrie T, Boelle E, Magherini E. Maison-Blanche P, et al. Among authors: volovat c. J Cardiovasc Pharmacol. 2013 Jun;61(6):495-504. doi: 10.1097/FJC.0b013e31828b73ff. J Cardiovasc Pharmacol. 2013. PMID: 23429593 Clinical Trial.
A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer.
Volovat SR, Ciuleanu TE, Koralewski P, Olson JEG, Croitoru A, Koynov K, Stabile S, Cerea G, Osada A, Bobe I, Volovat C. Volovat SR, et al. Among authors: volovat c. Oncotarget. 2020 Aug 18;11(33):3105-3117. doi: 10.18632/oncotarget.27684. eCollection 2020 Aug 18. Oncotarget. 2020. PMID: 32913555 Free PMC article.
Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review).
Volovat SR, Negru S, Stolniceanu CR, Volovat C, Lungulescu C, Scripcariu D, Cobzeanu BM, Stefanescu C, Grigorescu C, Augustin I, Lupascu Ursulescu C, Volovat CC. Volovat SR, et al. Among authors: volovat cc, volovat c. Exp Ther Med. 2021 May;21(5):535. doi: 10.3892/etm.2021.9967. Epub 2021 Mar 23. Exp Ther Med. 2021. PMID: 33815608 Free PMC article. Review.
61 results